Caris Life Sciences, Inc. · NASDAQ:CAI
Caris Life Sciences — Q1 2026 Earnings Presentation
14 slides from Caris Life Sciences's earnings presentation, May 7, 2026
Slide 1: Where Molecular Science Meets Artificial Intelligence
Where Molecular Science Meets Artificial Intelligence Q1 2026 Earnings Call May 7, 2026
Slide 2: Important Information and Disclaimer
Important Information and Disclaimer Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in t
Slide 3: Powerful Molecular Platform
Powerful Molecular Platform Broad Clinical Reach and Expanding Platform MI Profile (WES/WTS/IHC) Caris Assure (WES/WTS/CH) Caris ChromoSeq (WGS/WTS) MI Clarity (Digital AI) Heme Therapy Selection Early-Stage Breast Predictor Tissue-Based Therapy Selection Blood-Based Therapy Selection (Launched Apri
Slide 4: Strong Revenue Performance
Strong Revenue Performance Total Revenue Total Q1 2026 Revenue Breakdown ($ in millions) ($ in millions) Pharma R&D Services Molecular Profiling Services $216.2 $5.4 $5.4 $22.6 79% Tissue revenue increased 85% YOY $120.9 $6.8 Blood revenue increased 80% YOY $210.8 $114.1 $188.2 Tissue Blood Pharma Q
Slide 5: Q1 2026 Performance Highlights
Q1 2026 Performance Highlights Financial Highlights GAAP Revenue growth of 79% - from $121MM to $216MM Volume growth of 15% - completing 52,800 clinical cases Clinical ASP increase of 61% - from $2,488 to $3,996 GAAP gross margin of 65%, a ~1,800 bps increase GAAP Net Loss of $0.5MM and Po
Slide 6: Molecular Profiling Growth Driven by Volume and ASP Uplift
Molecular Profiling Growth Driven by Volume and ASP Uplift Molecular Profiling Services Revenue Molecular Profiling Services Volume (1) ($ in millions) Blood 52,800 Blood Tissue 45,800 9,200 Tissue 15% $210.8 5,800 $22.6 43,600 40,000 85% Q1 2025 Q1 2026 $114.1 Molecular Profiling Services Reported
Slide 7: Commercial Execution Driving Clinical Volume Growth
Commercial Execution Driving Clinical Volume Growth Re-alignment of Sales Organization completed in January 2026 Clinical Volume Commercial Highlights Completed Cases 15% 52,800 56,000+ 58% 70%+ 45,900 Quarterly run-rate of Caris Assure Orders approximately 56,000 volume growth electronically comple
Slide 8: Caris Detect Achieve 1 Results
Caris Detect Achieve 1 Results Whole-genome sequencing delivered 60.3% Stage I/II sensitivity with 99.2% asymptomatic specificity across a 3,014-subject high-risk cohort Deep Molecular Foundation Overall Achieve 1 Performance Caris Detect leverages Caris' molecular profiling Total results: 2,122 int
Slide 9: Additional Pipeline Solutions - Status
Additional Pipeline Solutions - Status TUMOR NAIVE TUMOR INFORMED WHOLE GENOME WHOLE EXOME WHOLE EXOME WHOLE GENOME WHOLE TRANSCRIPTOME WHOLE TRANSCRIPTOME Therapy Selection for the following: Breast cancer patients who are: MRD intended use: Intended use: PATIENT POPULATION • Acute Myeloid Leukemia
Slide 10: Q1 2026 Financial Overview
Q1 2026 Financial Overview Selected financial metrics All amounts rounded to nearest million except gross margin TOTAL REVENUE GROSS MARGIN(1) $216MM 65% Q1 2025 Q1 2026 Change +79% vs. Q1 2025 +1800 bps vs. Q1 2025 GAAP Total Revenue $121MM $216MM +79% ADJUSTED EBITDA(2) FREE CASH FLOW(2) Molecular
Slide 11: Molecular Profiling Services Performance in Q1 2026
Molecular Profiling Services Performance in Q1 2026 Q1 2026 Molecular Profiling Molecular Profiling Services Revenue: Reported revenue and ASP continued to benefit from favorable collections across both ($ in millions) MI Profile and Caris Assure Additional revenue from exceeding accrual on prior ye
Slide 12: Molecular Profiling Services Tailwinds
Molecular Profiling Services Tailwinds Commercial and Reimbursement Tailwinds Molecular Profiling Services Gross Margin (1) Covered Lives Tissue Mix Assure Growth Margin from additional revenue from exceeding accrual on period period cases 225MM+ >75% +58% Margin excluding additional revenue from ex
Slide 13: Reaffirming Full Year 2026 Guidance
Reaffirming Full Year 2026 Guidance Total Revenue $1.00BN – $1.02BN Full year 2026 revenue is expected to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to full 23% – 26% YoY year 2025. Molecular profiling revenue is expected to grow approx
Slide 14: Mission
Mission Caris was founded to make precision medicine a reality. We aim to fundamentally change the way disease is characterized and treated. We believe that more information is more power. And our philosophy is to provide every patient more power in the battle against disease.